Search

Your search keyword '"Nordström D"' showing total 369 results

Search Constraints

Start Over You searched for: Author "Nordström D" Remove constraint Author: "Nordström D"
369 results on '"Nordström D"'

Search Results

1. OP0092 INFECTIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH JAK-INHIBITORS COMPARED TO bDMARDs: FINDINGS FROM AN INTERNATIONAL COLLABORATION OF REGISTERS (THE “JAK-POT” STUDY)

2. POS0474 ULTRASOUND REMISSION RATES AFTER 1 YEAR ARE HIGH IN EARLY RA PATIENTS ON INDUCTION TREATMENT: RESULTS FROM THE RANDOMIZED NORD-STAR TRIAL

3. AB0758 CIRCULATING ADIPOKINES AND RESPONSE TO TREATMENT IN EARLY RHEUMATOID ARTHRITIS – DATA FROM THE RANDOMIZED NORD-STAR TRIAL

5. Blood chemokine levels are markers of disease activity but not predictors of remission in early rheumatoid arthritis

6. POS0344 BASDAI CUT-OFFS FOR DISEASE ACTIVITY CORRESPONDING TO ASDAS-ESR CUT-OFFS IN AXIAL SPONDYLARTHRITIS – RESULTS FROM THE EUROSPA COLLABORATION

7. POS0324 OBESITY IS A RISK FACTOR FOR POOR RESPONSE TO TREATMENT IN EARLY RHEUMATOID ARTHRITIS - A NORD-STAR SPIN-OFF STUDY

8. POS0632 TARGETING NET FORMATION IN EARLY RA PATIENTS; A SPIN-OFF STUDY FROM THE NORD-STAR

9. POS0374 HOW WELL DO EULAR/ASAS-EULAR AND NATIONAL TREATMENT RECOMMENDATIONS FOR PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS ALIGN? IS IT TIME FOR AN UPDATE OF NATIONAL TREATMENT RECOMMENDATIONS?

10. AB1602 CROSS COUNTRY DIFFERENCES IN B/TSDMARD PRESCRIPTION BEHAVIOR: ASSOCIATIONS BETWEEN SOCIOECONOMICS, REAL WORLD B/TSDMARD USE AND DISEASE OUTCOMES

11. OP0022 COMPARATIVE EFFECTIVENESS OF BIOLOGIC AND TARGETED SYNTHETIC DMARDS IN PSORIATIC ARTHRITIS ACCORDING TO COMORBIDITIES AT TREATMENT START: A NORDIC COLLABORATIVE STUDY BASED ON ENRICHED CLINICAL REGISTERS

12. OP0219 INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH JAK-INHIBITORS COMPARED TO BDMARDS: DATA FROM AN INTERNATIONAL COLLABORATION OF REGISTRIES (THE “JAK-POT” STUDY)

13. POS0249 SEX DIFFERENCES IN PATIENT-REPORTED OUTCOMES IN AXIAL SPONDYLOARTHRITIS PATIENTS TREATED WITH TUMOR NECROSIS FACTOR INHIBITORS: RESULTS FROM A MULTINATIONAL OBSERVATIONAL COHORT STUDY

14. CERTOLIZUMAB-PEGOL, ABATACEPT, TOCILIZUMAB OR ACTIVE CONVENTIONALTHERAPY IN EARLY RHEUMATOID ARTHRITIS: CLINICAL AND RADIOGRAPHIC 48-WEEKS RESULTS OF THE INVESTIGATOR-INITIATED RANDOMIZED NORD-STARTRIAL

15. OP0266 TREATMENT DISCONTINUATION DUE TO ADVERSE EVENTS AS AN OVERALL MEASURE OF TOLERANCE AND SAFETY OF JAK-INHIBITORS: AN INTERNATIONAL COLLABORATION OF REGISTRIES OF RHEUMATOID ARTHRITIS PATIENTS (THE “JAK-pot” STUDY).

16. OP0058 CERTOLIZUMAB-PEGOL, ABATACEPT, TOCILIZUMAB OR ACTIVE CONVENTIONAL THERAPY IN EARLY RHEUMATOID ARTHRITIS: CLINICAL AND RADIOGRAPHIC 48-WEEKS RESULTS OF THE INVESTIGATOR-INITIATED RANDOMIZED NORD-STAR TRIAL

17. POS0516 PLASMA CALPROTECTIN WAS ASSESSED IN MULTIPLE BIOLOGICAL TREATMENT STRATEGIES FOR EARLY RHEUMATOID ARTHRITIS

18. OP0059 PROFOUND ANTICOAGULANT EFFECTS OF INITIAL ANTIRHEUMATIC TREATMENTS IN EARLY RHEUMATOID ARTHRITIS PATIENTS: A NORD-STAR SPIN-OFF STUDY

20. OP0020 SEX DIFFERENCES IN EFFECTIVENESS OF FIRST-LINE TUMOR NECROSIS FACTOR INHIBITORS IN AXIAL SPONDYLOARTHRITIS; RESULTS FROM FIFTEEN COUNTRIES IN THE EuroSpA RESEARCH COLLABORATION NETWORK

21. Additional file 1 of The biological activity of serum bacterial lipopolysaccharides associates with disease activity and likelihood of achieving remission in patients with rheumatoid arthritis

22. Additional file 5 of The biological activity of serum bacterial lipopolysaccharides associates with disease activity and likelihood of achieving remission in patients with rheumatoid arthritis

23. Additional file 4 of The biological activity of serum bacterial lipopolysaccharides associates with disease activity and likelihood of achieving remission in patients with rheumatoid arthritis

24. Additional file 2 of The biological activity of serum bacterial lipopolysaccharides associates with disease activity and likelihood of achieving remission in patients with rheumatoid arthritis

25. Additional file 3 of The biological activity of serum bacterial lipopolysaccharides associates with disease activity and likelihood of achieving remission in patients with rheumatoid arthritis

27. INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH JAK-INHIBITORS COMPARED TO BDMARDS: DATA FROM AN INTERNATIONAL COLLABORATION OF REGISTRIES (THE "JAK-POT" STUDY).

28. POS0093 HETEROGENEITY IN ADVERSE EVENT ASSESSMENT BETWEEN COUNTRIES PARTICIPATING IN AN INTERNATIONAL COLLABORATION OF REGISTRIES OF RHEUMATOID ARTHRITIS PATIENTS USING JANUS KINASE INHIBITORS (THE JAK-POT STUDY)

29. OP0140 BIOLOGIC REFRACTORY DISEASE IN AXIAL SPONDYLOARTHRITIS - DEFINITION, PREVALENCE AND PATIENT CHARACTERISTICS. A COLLABORATION BETWEEN FIVE NORDIC BIOLOGIC REGISTRIES

30. POS0027 SECULAR TRENDS IN BASELINE CHARACTERISTICS, TREATMENT RETENTION AND RESPONSE RATES IN 27189 BIO-NAÏVE AXIAL SPONDYLOARTHRITIS PATIENTS INITIATING TNFI – RESULTS FROM THE EUROSPA COLLABORATION

31. OP0222 THE INCIDENCE OF INTERSTITIAL LUNG DISEASE IN PSORIATIC ARTHRITIS COMPARED TO RHEUMATOID ARTHRITIS. DATA FROM OVER 89 000 BDMARD TREATMENT COURSES DERIVED FROM FIVE NORDIC REGISTERS

32. Comparative effectiveness of JAK-inhibitors, TNF-inhibitors, abatacept and IL-6 inhibitors in an international collaboration of registers of rheumatoid arthritis patients (the 'JAK-POT' study)

37. OP0231 COMPARATIVE EFFECTIVENESS OF JAK-INHIBITORS, TNF-INHIBITORS, ABATACEPT AND IL-6 INHIBITORS IN AN INTERNATIONAL COLLABORATION OF REGISTERS OF RHEUMATOID ARTHRITIS PATIENTS (THE “JAK-POT” STUDY)

38. THU0394 COMPARISON OF TREATMENT RETENTION OF SECUKINUMAB AND TNF-INHIBITORS IN PSORIATIC ARTHRITIS. OBSERVATIONAL DATA FROM A NORDIC COLLABORATION.

39. OP0018 A MULTICENTER RANDOMIZED STUDY IN EARLY RHEUMATOID ARTHRITIS TO COMPARE ACTIVE CONVENTIONAL THERAPY VERSUS THREE BIOLOGICAL TREATMENTS: 24 WEEK EFFICACY RESULTS OF THE NORD-STAR TRIAL

40. FRI0534 PATIENT-REPORTED MEASURES OF DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS VARY ACROSS THE NORDIC COUNTRIES, RESULTS FROM A NORDIC COLLABORATION

41. OP0109 CO-MEDICATION WITH A CONVENTIONAL SYNTHETIC DMARD IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS IS ASSOCIATED WITH IMPROVED RETENTION OF TNF INHIBITORS: RESULTS FROM THE EUROSPA COLLABORATION

44. Human β-defensin 2 expression in oral epithelium:potential therapeutic targets in oral lichen planus

48. Smoking and response to rituximab in rheumatoid arthritis:results from an international European collaboration

Catalog

Books, media, physical & digital resources